Inhibrx, Inc. (NasdaqGM: INBX) Loss Submission Form

Kuznicki Law is investigating the proposed sale of Inhibrx, Inc. (NasdaqGM: INBX) to Sanofi (NasdaqGS: SNY).  Under the terms of the proposed transaction, shareholders of Inhibrx will receive $30.00 in cash, a contingent value right of $5.00 (conditioned upon the achievement of a regulatory milestone), and 0.25 shares of a new publicly traded company that will retain Inhibrx’s non-INBRX-101 assets, for each share of Inhibrx that they own. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.